Healthcare Industry News:  T-cell lymphoma 

Biopharmaceuticals Oncology Licensing Distribution

 News Release - January 2, 2018

PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin(R) (plitidepsin) With Megapharm in Israel

MADRID, January 2, 2018 -- (Healthcare Sales & Marketing Network) --PharmaMar (MCE: PHM) has announced today a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority.

According to the agreement Megapharm will register Aplidin® on behalf of PharmaMar and distribute the compound in both regions. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use.

Aplidin® is PharmaMar´s second most advanced anticancer drug which is currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The Company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma[i].

According to Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, "we are about to address our first strategic alliance with Megapharm for the commercialization of Aplidin® formultiple myeloma in Israel and the territory known as the Palestinian Authority. Our commitment is to bring a novel and first-in-class therapy to patients in need."

Miron Drucker, CEO of Megapharm, stated that "the agreement between PharmaMar and Megapharm offers a major advance for healthcare in our territory as Aplidin® provides a novel mechanism of action for treating multiple myeloma; we hope to bring access to the most innovative treatments to our patients in Israel and the territory known as the Palestinian Authority".


Source: PharmaMar

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.